Epidarex Capital – Portfolio Company Enterprise Therapeutics” Lead Program Acquired by Roche
In All, PortfolioEnterprise Therapeutics’ first-in-class TMEM16A potentiator program is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseases Epidarex Capital was the founding investor in Enterprise Therapeutics in 2015 and was instrumental in setting…